Life science investors close nearly $6 billion in new funds

Biotech and life sciences investors continue to draw in new funds even as the biotech stock indexes reach new lows.

On Wednesday, VC firm Bioluminescence Ventures launched with $477 million to invest in biotech startups. The firm was founded by Kouki Harasaki, who was previously a partner at M12, Microsoft’s corporate venture group, and Andreessen Horowitz. He also has a track record at pharmaceutical companies like Novartis and Baxalta.

Bioluminescence joined at least four other firms — OrbiMed, Sofinnova Partners, Abingworth, and Revelation Partners — in announcing new pools of capital in the last two weeks. Together, they have raised $5.94 billion.

Get unlimited access to award-winning journalism and exclusive events.

Experimental gene therapy seems to alleviate skeletal defects tied to rare inherited disease, study shows

LONDON — In 2021, a team of Italian researchers reported that an experimental gene therapy they had developed seemed to be correcting the metabolic issues

May 1, 2024

Hamilton Medical’s urgent ventilator notice deemed Class I recall by FDA

Dive Brief: Hamilton Medical’s recall of ventilators for a software problem was designated Class I by the U.S. Food and Drug Administration, the agency wrote

August 31, 2023

Groundbreaking research challenges traditional neurodivergent diagnoses

A new article introduces a dimensional approach to understanding the mental health needs of neurodivergent people.

September 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.